Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

Prior treatment

• Has received a non-autologous bone marrow transplant or has an active hematologic malignancy (i.e., leukemia or lymphoma)
• Current or prior history of PDAC or total pancreatectomy

Other

• Is unable to provide informed consent
• Is currently a prison inmate
• Is not able to speak or read English

• PDAC FAMILY HISTORY OR PDAC RELATED GENETIC MUTATIONS:
  • Age: 50 or older, plus at least one of the following:
  • Mutation unknown or absent:
  • 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject;
  • OR 2+ affected first degree relatives \[(FDR), defined as blood related parents, siblings, or children\]
  • Known pathogenic/likely pathogenic (P/LP) mutation in at least one of the following:
  • CDKN2A/p16, Peutz-Jeghers syndrome (PJS) serine/threonine kinase 11 (STK11), Hereditary pancreatitis with confirmed protease serine 1 (PRSS1)
  • OR 1+ or second degree relative (SDR) with PDAC and a known P/LP mutation in one or more of:
  • ATM, BRCA1, BRCA2, PALB2, Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), TP53
• HIGH-RISK OR WORRISOME PANCREATIC CYSTS:
  • 18 years of age or greater and meeting Fukuoka worrisome (FW) or Fukuoka high-risk (FHR) criteria
  • High risk stigmata:
  • Obstructive Jaundice in a patient with cystic lesion of the head of the pancreas
  • Enhancing mural nodule ≥ 5 mm
  • Main pancreatic duct ≥ 10 mm
  • Worrisome features:
  • Presence of pancreatic duct stricture, defined as focal pancreatic duct narrowing with upstream duct =\> 6 mm
  • Cyst ≥ 3 cm
  • Enhancing mural nodule \< 5 mm
  • Thickened/Enhancing cyst wall
  • Main duct size 5-9 mm
  • Pancreatitis
  • Lymphadenopathy
  • Increased CA 19-9
  • Cyst growth rate ≥ 5 mm /2 years